Close Menu

NEW YORK – Oxford Immunotec said on Tuesday that its third quarter revenues fell 8 percent year over year, driven in part by the impact of COVID-19 on its testing volumes.

For the three months ended Sept. 30, the firm reported revenues of $19.4 million compared to $21.2 million in the year-ago quarter, above the high end of its previously announced guidance range for Q3 of $18 million to $19 million and beating analysts' average estimate of $18.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.